Claims

1. ~~A pharmaceutical composition for topical administration comprising~~Use of the compound 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt ~~thereof in a pharmaceutically acceptable carrier~~in the manufacture of a medicament for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject, wherein a therapeutically effective dose of the medicament is to be topically administered to the skin or mucous membrane of the mammal subject.

2. ~~A pharmaceutical composition~~The use according to claim 1, ~~comprising~~ wherein the medicament comprises B-220 in an amount of 0.1-10% (w/w).

3. ~~A pharmaceutical composition~~The use according to claim 1, ~~comprising~~ wherein the medicament comprises B-220 in an amount of 0.5-5% (w/w).

4. ~~A pharmaceutical composition~~ The use according to any one of the claims 1-3, ~~comprising~~ wherein the medicament comprises at least one additional therapeutically active ingredient.

5. ~~A pharmaceutical composition~~The use according to claim 4, wherein the additional therapeutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anaesthetic agents, antiphlogistic agents and antiinflammatory agents.

6. ~~A pharmaceutical composition~~The use according to claim 5, wherein the additional therapeutically active ingredient is an antiphlogistic agent.

7. ~~A pharmaceutical composition~~The use according to claim 5, wherein the additional therapeutically active ingredient is an antiinflammatory agent.

8. ~~A pharmaceutical composition~~The use according to any one of the claims 4-7, wherein the additional therapeutically active agent is present in an amount of 0.005-5% (w/w).

~~9. A pharmaceutical composition according to any of claims 1-8 for use in the prophylaxis and/or treatment of a herpes virus infection in a mammal subject.~~

~~10~~9. ~~A pharmaceutical composition~~The use according to any one of the claims 1-~~9~~8, wherein the medicament is for dermal or mucosal treatment.

~~11~~10. ~~A pharmaceutical composition~~The use according to any one of the claims 1-~~10~~9, wherein the medicament is in the form of a cream, liquid, lotion, gel, spray, foam or ointment.

~~12~~11. ~~A~~ The use according to any one of the claims 1-10, wherein the medicament is provided in a patch, stick, spray dispenser, tube, or pen ~~containing a pharmaceutical composition according to any one of the claims 1-11~~.

~~13. The compound 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt for use in the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject by topical administration of a therapeutically effective dose thereof to the skin or mucous membrane of the mammal subject.~~

~~14. The compound according to claim 13, wherein an additional pharmaceutically active ingredient, is topically administered, in sequence or in combination with B-220 or its pharmaceutically acceptable salt.~~

~~15. The compound according to claim 14, wherein the additional pharmaceutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anaesthetic agents, antiphlogistic agents and antiinflammatory agents.~~

~~16. Use of a pharmaceutical composition according to any of claims 1-8 in the manufacture of a medicament for prophylaxis and/or treatment of a herpes virus infection in a mammal subject.~~

~~17. Use of a pharmaceutical composition according to any one of the claims 1-9 in the manufacture of a medicament for dermal or mucosal treatment.~~

~~18. Use of the compound 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject, wherein a therapeutically effective dose of the medicament is to be topically administered to the skin or mucous membrane of the mammal subject.~~

~~19. The use according to claim 18, wherein an additional pharmaceutically active ingredient is to be topically administered, in sequence or in combination with B-220 or its pharmaceutically acceptable salt.~~

~~20. The use according to claim 19, wherein the additional pharmaceutically active ingredient is selected from antiviral agents, antibiotics, analgesics, anaesthetic agents, antiphlogistic agents and antiinflammatory agents.~~